| Date: | 5/5/2023 | |
|-------------------------------|---|--|
| Your Name: | Andre Lunz | |
| Manuscript Title: | Minimum 20-year results of the first 121 consecutive total hip replacements using a cementless, press-fit acetabular cup in young patients | |
| Manuscript Number (if known): | AO-2022-451/R2 RESUBMISSION - (16723) | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | | ities with whom you have this or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|------------|--|---|
| | | | Time frame: Since the initial planning | of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | * | Click the tab key to add additional rows. |
| | the state of the strength of the | 1 10 - 1 A | Time frame: past 36 month | ns Participant and a state of the |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | | 2 2 4 4 |
| 3 | Royalties or licenses | None | | |

ICMJE Disclosure Form

| | | Name all entities with whom you have this Specifications/Comments (e.g., if payments visual paym | were |
|----|--|--|------|
| 4 | Consulting fees | ☑ None | |
| 5 | Payment or ,honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
| 6 | Payment for expert testimony | ☑ None | |
| 7 | Support for attending meetings and/or travel | None | |
| 8 | Patents planned, issued or pending | None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|--|---|
| 11 | Stock or stock | None | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | |
| 13 | Other financial or non-financial interests | None | |

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

3

,

| Date: | 5/5/2023 | |
|-------------------------------|---|--|
| Your Name: | Moritz von Falkenhayn | |
| Manuscript Title: | Minimum 20-year results of the first 121 consecutive total hip replacements using a cementless, press-fit acetabular cup in young patients | |
| Manuscript Number (if known): | AO-2022-451/R2 RESUBMISSION - (16723) | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| 100 | an a | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----|---|--|---|
| | | Time frame: Since the initial planning | of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | ⊠ None | Click the tab key to add additional rows. |
| | | Time frame: past 36 month | is the second |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | ⊠ None | |
| 3 | Royalties or licenses | None | |

| | a section | Name all entities with whom you have this relationship or indicate none (add rows as needed)Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|---|
| 4 | Consulting fees , | None |
| 5 | Payment or ,honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None |
| 6 | Payment for expert testimony | None |
| 7 | Support for attending meetings and/or travel | None |
| 8 | Patents planned, issued or pending | None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|---|---|
| 11 | Stock or stock | ⊠ None | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | |
| 13 | Other financial or non-financial interests | None | |

Please place an "X" next to the following statement to indicate your agreement:

3

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

| Date: | 5/5/2023 |
|-------------------------------|---|
| Your Name: | Tobias Reiner |
| Manuscript Title: | Minimum 20-year results of the first 121 consecutive total hip replacements using a cementless, press-fit acetabular cup in young patients |
| Manuscript Number (if known): | AO-2022-451/R2 RESUBMISSION - (16723) |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|--|
| | | Time frame: Since the initial plannin | g of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | ☑ None ☑ | Click the tab key to add additional rows. |
| | | | |
| 2 | Grants or contracts from any entity (if not indicated in item ·#1 above). | None | |
| 3 | Royalties or licenses | None | |

| 14 | an a sa garaga | Name all entities with whom you have this relationship or indicate none (add rows as needed)Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|---|
| 4 | Consulting fees | ☑ None □ □ □ □ |
| 5 | Payment or ,honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None |
| 6 | Payment for expert testimony | None |
| 7 | Support for attending meetings and/or travel | None |
| 8 | Patents planned, issued or pending | None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ⊠ None |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|--|---|
| 11 | Stock or stock | ⊠ None | |
| | | and the second sec | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | |
| 13 | Other financial or non-financial interests | None | |

| Date: | 5/5/2023 |
|-------------------------------|---|
| Your Name: | Christian Merle |
| Manuscript Title: | Minimum 20-year results of the first 121 consecutive total hip replacements using a cementless, press-fit acetabular cup in young patients |
| Manuscript Number (if known): | AO-2022-451/R2 RESUBMISSION - (16723) |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | | with whom you hav licate none (add rov | | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|------|---|------------------|---|
| | | Ti | me frame: Since the | initial planning | of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | | • | Click the tab key to add additional rows. |
| | | | Time frame: | past 36 month | S. S |
| 2 | Grants or contracts from any entity (if not , indicated in item #1 above). | None | | | • |
| 3 | Royalties or licenses | None | | | |

| 1.10 | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution) |
|------|--|--|
| 4 | Consulting fees , | None |
| 5 | Payment or ,honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None |
| 6 | Payment for expert testimony | None |
| 7 | Support for attending meetings and/or travel | None |
| 8 | Patents planned, issued or pending | None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None |

12/13/2021

| | | Name all entities with whom you have this relationship or indicate none (add rows as neede | Specifications/Comments (e.g., if payments were ad) made to you or to your institution) |
|----|--|---|--|
| 11 | Stock or stock | None | |
| | | | |
| 12 | Receipt of equipment, | None | 2 |
| | materials, drugs, | | |
| | medical writing, gifts or other services | × | |
| | | | |
| 13 | Other financial or non-financial | None | |
| | , interests | | |
| | | | |
| | | | |

| Date: | 5/5/2023 | |
|-------------------------------|---|---|
| Your Name: | Sebastian Jaeger | × |
| Manuscript Title: | Minimum 20-year results of the first 121 consecutive total hip replacements using a cementless, press-fit acetabular cup in young patients | 8 |
| Manuscript Number (if known): | AO-2022-451/R2 RESUBMISSION - (16723) | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | - | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial planning | of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | ⊠ None | Click the tab key to add additional rows. |
| | | Time frame: past 36 month | IS |
| 2 | Grants or contracts from any entity (if not 'indicated in item #1 above). | None | |
| 3 | Royalties or licenses | None | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|--|---|
| 4 | Consulting fees | ⊠ None | |
| 5 | Payment or ,honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
| 6 | Payment for expert testimony | ☑ None | · · |
| 7 | Support for attending meetings and/or travel | None | |
| 8 | Patents planned, issued or pending | ⊠ None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|--|---|
| 11 | Stock or stock •options | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | |
| 13 | Other financial or non-financial interests | None | |

| Date: | 5/5/2023 |
|-------------------------------|---|
| Your Name: | Moritz M. Innmann |
| Manuscript Title: | Minimum 20-year results of the first 121 consecutive total hip replacements using a cementless, press-fit acetabular cup in young patients |
| Manuscript Number (if known): | AO-2022-451/R2 RESUBMISSION - (16723) |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| 224 15 | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|--------|---|--|---|
| | ten panon de | Time frame: Since the initial planning | of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | Click the tab key to add additional rows. |
| | | Time frame: past 36 mont | ns Sector |
| 2 | Grants or contracts from any entity (if not 'indicated in item #1 above). | None | |
| 3 | Royalties or licenses | ☑ None | |

| t tap | and the second second | Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----------|--|--|
| 4 | Consulting fees | None |
| 5 | Payment or ,honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None |
| 6 | Payment for expert testimony | None |
| 7 | Support for attending meetings and/or travel | None |
| 8 | Patents planned, issued or pending | None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None |

| 9 | Name all entities with whom you have relationship or indicate none (add rows | |
|---|---|---|
| Stock or stock options | ⊠ None | |
| | Contraction of the spectra structure of | |
| Receipt of equipment, materials, drugs, medical writing, gifts or other | None | |
| Other financial or | ⊠ None | |
| non-financial interests | | |
| | options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-financial | relationship or indicate none (add rows Stock or stock options Image: None Receipt of equipment, materials, drugs, medical writing, gifts or other services Image: None Other financial or non-financial Image: None |

| Date: | 5/5/2023 |
|-------------------------------|---|
| Your Name: | Marcus R. Streit |
| Manuscript Title: | Minimum 20-year results of the first 121 consecutive total hip replacements using a cementless, press-fit acetabular cup in young patients |
| Manuscript Number (if known): | AO-2022-451/R2 RESUBMISSION - (16723) |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|--|
| | | Time frame: Since the initial plannin | g of the work |
| 1 | Àll support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | Click the tab key to add additional rows. |
| | | Time frame: past 36 mon | ths |
| 2 | Grants or contracts from 'any entity (if not indicated in item #1 above). | ⊠ None | |
| 3 | Royalties or licenses | None | |

1

ICMJE Disclosure Form

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed)Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|---|
| 4 | Consulting fees , | ☑ None |
| 5 | Payment or ,honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None |
| 6 | Payment for expert testimony | ⊠ None |
| 7 | Support for attending meetings and/or travel | None |
| 8 | Patents planned, issued or pending | None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|--|---|
| 11 | Stock or stock | ⊠ None | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical writing, | None | |
| | gifts or other services | х Х | |
| 13 | Other financial or non-financial interests | None | |
| | | | |

| Date: | 5/5/2023 | |
|-------------------------------|---|---|
| Your Name: | Tobias Renkawitz | |
| Manuscript Title: | Minimum 20-year results of the first 121 consecutive total hip replacements using a cementless, press-fit acetabular cup in young patients | × |
| Manuscript Number (if known): | AO-2022-451/R2 RESUBMISSION - (16723) | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| | | Time frame: Since the initial planning | of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for | None | Click the tab key to add additional rows. |
| | this item. | | |
| | | Time frame: past 36 month | s |
| 2 | Grants or •contracts from | □ None | * |
| | any entity (if not | German Research Foundation (DFG) | DGOOC |
| | indicated in item | Arbeitsgemeinschaft Endoprothetik (AE) | BVOU |
| | #1 above). | DGOU | DePuy International |
| | | Otto Bock Foundation | Deutsche Arthrose Hilfe |
| | | Aesculap, Zimmer | Stiftung Oskar Helene Heim Berlin |
| | | Vielberth Foundation Regensburg | German Ministry of Education and Research |
| | | German Federal Ministry of Economic Cooperation and Development | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|--|---|
| 3 | Royalties or licenses | None | |
| 4 | Consulting fees | ☑ None | |
| 5 | Payment or honoraria for lectures, presentations, 'speakers bureaus, manuscript writing or educational events | None | |
| 6 | , Payment for expert testimony | Image: None | |
| 7 | Support for 'attending meetings and/or travel | None | |
| 8 | Patents planned, ,issued or pending | None | |
| 9 | Participation on a Data Safety 'Monitoring Board or Advisory Board | None | |
| 10 | Leadership or fiduciary role in other board, | ⊠ None | |

12/13/2021

ICMJE Disclosure Form

| ia. | | Name all entities with whom you have this relationship or indicate none (add rows as need | ded) Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----|---|---|--|
| | society, committee or advocacy group, paid or unpaid | | |
| 11 | Stock or stock options | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | |
| 13 | .Other financial or non-financial interests | Image: None | |

.